Correlation between genotype frequencies of VDR gene polymorphisms and clinicopathological characteristics in PCa patient group
SNPs
BsmI N (%)
ApaI N (%)
TaqI N (%)
BB
Bb
bb
AA
Aa
aa
TT
Tt
tt
PSA (ng/mL)
< 4
5 (50%)
2 (20%)
3 (30%)
4 (40%)
5 (50%)
1 (10%)
2 (20%)
5 (50%)
3 (30%)
4–10
3 (14.3%)
7 (33.3%)
11 (52.4%)
8 (38.1%)
9 (42.9%)
4 (19%)
9 (42.9%)
10 (47.6%)
2 (9.5%)
> 10
8 (11.9%)
28 (41.8%)
31 (46.3%)
29 (43.3%)
29 (43.3%)
9 (13.4%)
29 (43.3%)
29 (43.3%)
9 (13.4%)
p-value
0.045*
0.951
0.492
Pathological Gleason score
< 7
1 (6.7%)
7 (46.7%)
7 (46.7%)
4 (26.7%)
8 (53.3%)
3 (20%)
6 (40%)
8 (53.3%)
1 (6.7%)
7 (3 + 4)
2 (15.4%)
4 (30.8%)
7 (53.8%)
5 (38.5%)
8 (61.5%)
0 (0%)
8 (61.5%)
4 (30.8%)
1 (7.7%)
7 (4 + 3)
2 (14.3%)
4 (28.6%)
8 (57.1%)
10 (71.4%)
1 (7.1%)
3 (21.4%)
6 (42.9%)
4 (28.6%)
4 (28.6%)
> 7
7 (22.6%)
11 (35.5%)
13 (41.9%)
13 (41.9%)
15 (48.4%)
3 (9.7%)
11 (35.5%)
15 (48.4%)
5 (16.1%)
p-value
0.808
0.049*
0.411
Pathological T-stage
T1
4 (10.5%)
16 (42.1%)
18 (47.4%)
13 (34.2%)
20 (52.6%)
5 (13.2%)
10 (26.3%)
24 (63.2%)
4 (10.5%)
T2
6 (16.2%)
11 (29.7%)
20 (54.1%)
17 (45.9%)
13 (35.1%)
7 (18.9%)
20 (54.1%)
12 (32.4%)
5 (13.5%)
T3
1 (12.5%)
3 (37.5%)
4 (50%)
4 (50%)
3 (37.5%)
1 (12.5%)
4 (50%)
1 (12.5%)
3 (37.5%)
T4
5 (38.5%)
4 (30.8%)
4 (30.8%)
7 (53.8%)
6 (46.2%)
0 (0%)
5 (38.5%)
6 (46.2%)
2 (15.4%)
p-value
0.354
0.522
0.042*
Medical background
Yes
9 (23.7%)
13 (34.2%)
16 (42.1%)
15 (39.5%)
18 (47.4%)
5 (13.2%)
15 (39.5%)
17 (44.7%)
6 (15.8%)
No
7 (11.3%)
25 (40.3%)
30 (48.4%)
27 (43.5%)
26 (41.9%)
9 (14.5%)
26 (41.9%)
28 (45.2%)
8 (12.9%)
p-value
0.260
0.868
0.916
Surgical history
Yes
8 (30.8%)
8 (30.8%)
10 (38.5%)
10 (38.5%)
11 (42.3%)
5 (19.2%)
10 (38.5%)
8 (30.8%)
8 (30.8%)
No
8 (10.8%)
30 (40.5%)
36 (48.6%)
32 (43.2%)
33 (44.6%)
9 (12.2%)
31 (41.9%)
37 (50%)
6 (8.1%)
p-value
0.058
0.666
0.013*
SNPs: single nucleotide polymorphisms; PSA: prostate-specific antigen; * statistically significant
Declarations
Acknowledgments
The authors would like to thank Hassan II University of Casablanca, Faculty of Sciences and Techniques—Mohammedia, the members of the team of Virology, Oncology and Biotechnologies, Laboratory of Virology, Oncology, Biosciences, Environment and New Energies. As well as the Laboratory of Research and Biosafety of Mohammed V Construction Teaching Hospital in Rabat, for their help during sample collection.
Author contributions
KN: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing—original draft. AL: Resources, Writing—review & editing. IT: Data curation, Investigation. KAT: Investigation, Methodology. MM and AA: Resources. KE: Data curation, Resources. MB: Supervision, Writing—review & editing. MME: Conceptualization, Data curation, Formal analysis, Investigation, Supervision, Validation, Writing—review & editing. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
The study protocol was approved by the Ethics Committee for Biomedical Research of the Faculty of Medicine and Pharmacy of Casablanca, Morocco (No. 3/2018/April 30, 2018).
Consent to participate
The informed consent to participate in the study was obtained from all participants.
Consent to publication
Not applicable.
Availability of data and materials
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2018;68:394–424. [DOI] [PubMed]
Nabil K, Laraqui A, Mrabti M, Ameur A, Ennibi K, Benhessou M, et al. Molecular evaluation of Herpes simplex virus type 2 infection in blood samples among men with prostate cancer.TMJ. 2022;45:7445–53.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014.CA Cancer J Clin. 2014;64:9–29. [DOI] [PubMed]
De Nunzio C, Lombardo R. Best of 2023 in Prostate Cancer and Prostatic Diseases.Prostate Cancer Prostatic Dis. 2024;27:165–7. [DOI] [PubMed]
Bostwick DG, Burke HB, Djakiew D, Euling S, Ho S, Landolph J, et al. Human prostate cancer risk factors.Cancer. 2004;101:2371–490. [DOI] [PubMed]
Yang J, Qian LX, Wu HF, Xu ZQ, Sui YG, Wang XR, et al. Genetic polymorphisms in the cytochrome P450 1A1 and 2E1 genes, smoking, drinking and prostate cancer susceptibility: A case-control study in a Han nationality population in Southern China.Int J Urol. 2006;13:773–80. [DOI] [PubMed]
Studzinski GP, Moore DC. Sunlight—can it prevent as well as cause cancer?Cancer Res. 1995;55:4014–22. [PubMed]
Yuan C, Shui IM, Wilson KM, Stampfer MJ, Mucci LA, Giovannucci EL. Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer.Int J Cancer. 2019;144:2401–7. [DOI] [PubMed] [PMC]
Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland).Cancer Causes Control. 2000;11:847–52. [DOI] [PubMed]
Zhao XY, Peehl DM, Navone NM, Feldman D. 1α,25-Dihydroxyvitamin D3 Inhibits Prostate Cancer Cell Growth by Androgen-Dependent and Androgen-Independent Mechanisms.Endocrinology. 2000;141:2548–56. [DOI] [PubMed]
Wu-Wong JR. Vitamin D receptor: A highly versatile nuclear receptor.Kidney Int. 2007;72:237–9. [DOI] [PubMed]
Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, et al. Structural Organization of the Human Vitamin D Receptor Chromosomal Gene and Its Promoter.Mol Endocrinol. 1997;11:1165–79. [DOI] [PubMed]
Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.Cancer Res. 1994;54:805–10. [PubMed]
Swamy N, Chen TC, Peleg S, Dhawan P, Christakos S, Stewart LV, et al. Inhibition of Proliferation and Induction of Apoptosis by 25-Hydroxyvitamin D3-3β-(2)-Bromoacetate, a Nontoxic and Vitamin D Receptor-Alkylating Analog of 25-hydroxyvitamin D3 in Prostate Cancer Cells.Clin Cancer Res. 2004;10:8018–27. [DOI] [PubMed]
Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, et al. Vitamin D Receptor Protein Expression in Tumor Tissue and Prostate Cancer Progression.J Clin Oncol. 2011;29:2378–85. [DOI] [PubMed] [PMC]
Uitterlinden AG, Fang Y, Van Meurs JB, Pols HAP, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms.Gene. 2004;338:143–56. [DOI] [PubMed]
Huang SP, Huang CY, Wu WJ, Pu YS, Chen J, Chen YY, et al. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.Int J Cancer. 2006;119:1902–7. [DOI] [PubMed]
Rai V, Abdo J, Agrawal S, Agrawal DK. Vitamin D Receptor Polymorphism and Cancer: An Update.Anticancer Res. 2017;37:3991–4003. [DOI] [PubMed]
Kang S, Zhao Y, Wang L, Liu J, Chen X, Liu X, et al. Lack of association between the risk of prostate cancer and vitamin D receptor Bsm I polymorphism: a meta-analysis of 27 published studies.Cancer Manag Res. 2018;10:2377–87. [DOI] [PubMed] [PMC]
Kambale PR, Haldar D, Kabi BC, Kambale KP. Study of Vitamin D Receptor Gene Polymorphism (FokI, TaqI and ApaI) Among Prostate Cancer Patients in North India.J Clin Diagn Res. 2017;11:BC05–8. [DOI] [PubMed] [PMC]
Lin VC, Huang SP, Ting HJ, Ma WL, Yu CC, Huang CY, et al. Vitamin D receptor-binding site variants affect prostate cancer progression.Oncotarget. 2017;8:74119–28. [DOI] [PubMed] [PMC]
Norman AW. Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system.Am J Clin Nutr. 1998;67:1108–10. [DOI] [PubMed]
Carnevale V, Modoni S, Pileri M, Di Giorgio A, Chiodini I, Minisola S, et al. Longitudinal Evaluation of Vitamin D Status in Healthy Subjects from Southern Italy: Seasonal and Gender Differences.Osteoporos Int. 2001;12:1026–30. [DOI] [PubMed]
Javanmard A, Mohammadabadi MR, Zarrigabayi GE, Gharahedaghi AA, Nassiry MR, Javadmansh A, et al. Polymorphism within the intron region of the bovine leptin gene in Iranian Sarabi cattle (Iranian Bos taurus).Genetika. 2008;44:570–3. [PubMed]
Mohammadabadi M, Oleshko V, Oleshko O, Heiko L, Starostenko I, et al. Using Inter Simple Sequence Repeat Multi-Loci Markers for Studying Genetic Diversity in Guppy Fish.Turk J Fish Aquat Sci. 2021;21:603–13. [DOI]
Mohammadabadi MR, Tohidinejad F. Characteristics Determination of Rheb Gene and Protein in Raini Cashmere Goat.Iran J Appl Anim Sci. 2017;7:289–95.
Saadatabadi LM, Mohammadabadi M, Nanaei HA, Ghanatsaman ZA, Stavetska RV, Kalashnyk O, et al. Unraveling candidate genes related to heat tolerance and immune response traits in some native sheep using whole genome sequencing data.Small Ruminant Res. 2023;225:107018. [DOI]
Mohammadabadi MR, Torabi A, Tahmourespoor M, Baghizadeh A, Esmailizadeh Koshkoie A, Mohammadi A. Analysis of bovine growth hormone gene polymorphism of local and Holstein cattle breeds in Kerman province of Iran using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP).Afr J Biotechnol. 2010;9:6848–52.
Shokri S, Khezri A, Mohammadabadi M, Kheyrodin H. The expression of MYH7 gene in femur, humeral muscle and back muscle tissues of fattening lambs of the Kermani breed.Agric Biotechnol J. 2023;15:217–36. [DOI]
Torkko K, Till C, Tangen CM, Goodman PJ, Song X, Schenk JM, et al. Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial.Cancer Prev Res (Phila). 2020;13:521–30. [DOI] [PubMed] [PMC]
Onen IH, Ekmekci A, Eroglu M, Konac E, Yesil S, Biri H. Association of Genetic Polymorphisms in Vitamin D Receptor Gene and Susceptibility to Sporadic Prostate Cancer.Exp Biol Med (Maywood). 2008;233:1608–14. [DOI] [PubMed]
Fontaine V, Mascaux C, Weyn C, Bernis A, Celio N, Lefèvre P, et al. Evaluation of Combined General Primer-Mediated PCR Sequencing and Type-Specific PCR Strategies for Determination of Human Papillomavirus Genotypes in Cervical Cell Specimens.J Clin Microbiol. 2007;45:928–34. [DOI] [PubMed] [PMC]
Hung CH, Hu TH, Lu SN, Chen CH, Wang JH, Lee CM. Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C.J Formos Med Assoc. 2016;115:278–83. [DOI] [PubMed]
Li L, Wu B, Yang L, Yin G, Wei W, Sui S, et al. Association of vitamin D receptor gene polymorphisms with pancreatic cancer: A pilot study in a North China Population.Oncol Lett. 2013;5:1731–5. [DOI] [PubMed] [PMC]
Nair R, Maseeh A. Vitamin D: The “sunshine” vitamin.J Pharmacol Pharmacother. 2012;3:118–26. [PubMed] [PMC]
Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, et al. Vitamin D–Related Genetic Variation, Plasma Vitamin D, and Risk of Lethal Prostate Cancer: A Prospective Nested Case-Control Study.J Natl Cancer Inst. 2012;104:690–9. [DOI] [PubMed] [PMC]
Patiño-García B, Arroyo C, Rangel-Villalobos H, Soto-Vega E, Velarde-Félix JS, Gabilondo F, et al. Association between polymorphisms of the androgen and vitamin D receptor genes with prostate cancer risk in a Mexican population.Rev Invest Clin. 2007;59:25–31. [PubMed]
Nunes SBR, de Matos Oliveira F, Neves AF, Araujo GR, Marangoni K, Goulart LR, et al. Association of vitamin D receptor variants with clinical parameters in prostate cancer.Springerplus. 2016;5:364. [DOI] [PubMed] [PMC]
Chen L, Wei J, Zhang S, Lou Z, Wang X, Ren Y, et al. Association of VDR gene TaqI polymorphism with the susceptibility to prostate cancer in Asian population evaluated by an updated systematic meta-analysis.Onco Targets Ther. 2018;11:3267–80. [DOI] [PubMed] [PMC]
Wall JD, Pritchard JK. Haplotype blocks and linkage disequilibrium in the human genome.Nat Rev Genet. 2003;4:587–97. [DOI] [PubMed]
Jingwi EY, Abbas M, Ricks-Santi L, Winchester D, Beyene D, Day A, et al. Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men.Anticancer Res. 2015;35:1549–58. [PubMed] [PMC]
Nabil K, Azmi H, Najih M, Tadlaoui KA, Jouali F, Benhessou M, et al. Association Between Deficient Levels of Vitamin D and Increased Risk of PCa among Moroccan population: A Case-Control Study.BNIHS. 2023;141:3595–605.
NABIL K, BENHESSOU M, ENNAJI MM. The investigation of the deficiency of vitamin D in Moroccan healthy population and the linkage with prostate specific antigen.Int Med J (1994). 2023;30:8909–17.
Kang S, Zhao Y, Wang L, Liu J, Chen X, Liu X, et al. Vitamin D receptor Taq I polymorphism and the risk of prostate cancer: a meta-analysis.Oncotarget. 2017;9:7136–47. [DOI] [PubMed] [PMC]
Ntais C, Polycarpou A, Ioannidis JPA. Vitamin D Receptor Gene Polymorphisms and Risk of Prostate Cancer: A Meta-analysis.Cancer Epidemiol Biomarkers Prev. 2003;12:1395–402. [PubMed]
Daremipouran MR, Beyene D, Apprey V, Naab TJ, Kassim OO, Copeland RL Jr, et al. The Association of a Novel Identified VDR SNP With Prostate Cancer in African American Men.Cancer Genomics Proteomics. 2019;16:245–55. [DOI] [PubMed] [PMC]
El Ezzi AA, Boyko VG, Baker MT, Zaidan WR, Hraiki KM, El Saidi MA, et al. Association of Some Polymorphisms in the VDR Gene, CYP17 Gene and SRD5A2 Gene and Prostate Cancer among Lebanese Men.Asian Pac J Cancer Prev. 2017;18:93–100. [DOI] [PubMed] [PMC]
Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL. Vitamin D Pathway Gene Variants and Prostate Cancer Risk.Cancer Epidemiol Biomarkers Prev. 2009;18:1929–33. [DOI] [PubMed] [PMC]
